We read a lot of research. As a physician-led ketamine clinic that’s completed over 5,000 infusions, staying current with the science isn’t optional, it’s how we serve our patients. And one newsletter we keep coming back to is Tricycle Day, a 3x/week publication covering the latest in psychedelic research, policy, and business. Their June 10 issue had three stories worth talking about.
We recommend subscribing yourself.
The Postpartum Depression Trial That Made Us Stop Scrolling
A Phase 2a trial published in the Journal of Clinical Psychiatry treated 10 women with moderate-to-severe postpartum depression using vaporized mebufotenin — a synthetic, amphibian-free version of 5-MeO-DMT. The results were, to borrow Tricycle Day’s word for it, bonkers.
By day 8, depression scores had dropped by nearly 96%. All 10 patients hit both response and remission criteria — first measured just two hours after their final dose. Maternal functioning improved by 56%. No serious adverse events. Everyone went home the same day.
Now, the caveats are real: 10 patients, no placebo group, only one week of follow-up. This is early-stage science. But here’s what strikes us as clinicians: postpartum depression affects roughly 1 in 5 new mothers, and the treatment options are genuinely limited. The fact that a single compound can move the needle that dramatically and that quickly is exactly the kind of signal that deserves a larger, controlled trial.
What it tells us at the brain level: this is consistent with what we see with ketamine. When you rapidly shift the brain’s neuroplasticity window, things that felt impossible to feel — hope, connection, relief — can suddenly become accessible. The mechanism is different, but the principle rhymes. Fast-acting treatments that work on the brain rather than around it represent a fundamentally different approach to depression, and it’s one we believe in.
Here’s the problem right now — NOT available any time soon in Indiana. But IV ketamine therapy is available now, works through the same neuroplasticity mechanism, and is physician-supervised at our Greenwood clinic.
An Alzheimer’s Case Report That Has Neurologists Talking
This one is more speculative, but we think it’s worth knowing about. Researchers in Brazil published a case report about a woman in her 80s, a decade into her Alzheimer’s diagnosis, who had been largely nonverbal for five years. After a high dose of psilocybin mushrooms, about 19 hours later, she began telling stories about her life. Over the following weeks, she regained urinary continence, started walking and dressing herself, made eye contact, and cracked jokes.
A single case is not a clinical trial. We want to be clear about that. But as Tricycle Day noted: research has to start somewhere, and this isn’t the first time psychedelics have surprised scientists studying neurodegeneration. The first psilocybin-for-Parkinson’s study found motor function improvements nobody predicted.
From where we sit — at the intersection of emergency medicine and brain health — this is worth watching closely. The pattern emerging across these compounds is one of neuroplasticity: the brain’s ability to rewire itself. That’s the same mechanism we work with every day through IV ketamine. Whether psilocybin can meaningfully support neurodegeneration is an open question. But it’s now one that serious researchers are asking.
The Legislative Momentum Is Real
Connecticut just expanded its psychedelic therapy pilot program — originally limited to veterans, first responders, and healthcare workers — to any adult 18+ who meets clinical criteria. The bill cleared the state Senate 35-0. That’s not a close vote. That’s a signal.
With Trump’s executive order putting $50 million in matching funds on the table for states with active psychedelic research programs, the financial incentive for state legislatures is now concrete. More states are going to move. The question is less if and more when and how.
For our patients in Indiana, this matters. The landscape of what’s legally available, and what’s coming, is shifting faster than most people realize. Part of our job is to help you understand where ketamine fits in that landscape today — and where other therapies may fit in the future.
Our Take
The throughline across all three of these stories is the same thing we talk about every day in our clinic: the brain is more plastic, more responsive, and more healable than we were taught to believe. Postpartum depression doesn’t have to be a years-long struggle. Alzheimer’s may not be as irreversible as we assumed. And the political will to fund this research is, finally, building.
We’ll keep reading and sharing what we find. If you want to go deeper on Tricycle Day’s full coverage, read their June 10 issue here — and subscribe. It’s the best weekly briefing on where this field is heading.
And if any of this has you thinking about your own brain health — whether you’re a new mom who’s been struggling, someone who’s tried everything for depression or anxiety, or just someone who wants to understand what’s possible — book a free consultation with our team. We’re here to answer your questions honestly.
Frequently Asked Questions
Is IV ketamine therapy available in Indiana?
Yes. IV ketamine therapy is federally legal and available right now at AlphaOmega Wellness in Greenwood, Indiana — serving patients from Indianapolis, Carmel, Fishers, and across Central Indiana. You don’t need to wait for any new legislation.
Is ketamine related to the psychedelics being studied in this research?
Ketamine is not classified as a classic psychedelic, but it shares a key mechanism with many of the compounds being studied: neuroplasticity. It works by rapidly rewiring the brain’s synaptic connections, which is the same principle behind the dramatic results seen in the postpartum depression and Alzheimer’s research above. It’s the only medicine in this category that’s currently legal and physician-supervised in Indiana.
Can IV ketamine help with postpartum depression?
IV ketamine is not currently FDA-approved specifically for postpartum depression, but it has strong evidence for treatment-resistant depression broadly — and postpartum depression is a form of depression. Many of our patients have found significant relief. We evaluate each patient individually during a free consultation to determine whether ketamine therapy is appropriate.
What does neuroplasticity mean and why does it matter?
Neuroplasticity is the brain’s ability to form new connections and reorganize itself. Chronic depression, PTSD, and trauma physically shrink key areas of the brain. Ketamine — and the compounds being studied in psychedelic research — works by rapidly stimulating the growth of new synaptic connections, essentially giving the brain a window to rewire. This is why results can happen in hours rather than months.
How do I find out if ketamine therapy is right for me?
The best first step is a free consultation with our team at AlphaOmega Wellness. Dr. Dee Bonney and Megan Bonney, PMHNP, will review your history, answer every question, and give you an honest assessment — no pressure, no obligation. Schedule here or call us at 317-300-4091.